Filing summary
Entity mismatch: The metadata names Opus Genetics, Inc., but the supplied Form 10-Q is for Rexahn Pharmaceuticals, Inc. This summary reflects the filing text, not Opus Genetics.
Business context and reporting period
Rexahn is a clinical-stage oncology biopharmaceutical company with no commercial revenue. This unaudited report covers the quarter ended March 31, 2018, compared with the quarter ended March 31, 2017. Its principal active clinical candidates were RX-3117 and RX-5902; the company also described plans to wind down its internally funded RX-0201 metastatic kidney cancer trial.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 or prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.06 million | $2.26 million |
| General and administrative expense | $1.83 million | $1.69 million |
| Net loss | $2.07 million | $21.61 million |
| Net loss per share | $0.07 | $0.91 |
| Operating cash used | $5.60 million | $4.17 million |
| Cash and cash equivalents | $6.30 million | $8.90 million at Dec. 31, 2017 |
| Marketable securities | $14.88 million | $17.93 million at Dec. 31, 2017 |
| Total liabilities | $7.58 million | $11.52 million at Dec. 31, 2017 |
Cash plus marketable securities totaled approximately $21.18 million at quarter-end, down from $26.83 million at year-end. Investing activities provided $3.00 million, mainly from security redemptions; financing activities provided no cash. No conventional borrowing or debt balance is reported in the supplied balance sheet. Margins are not meaningful because the company had no revenue.
Material changes and unusual items
- R&D expense rose 79.4%, mainly because of drug-manufacturing campaigns and higher clinical-trial activity. Manufacturing costs were approximately $1.25 million versus $0.29 million a year earlier.
- The much smaller reported net loss largely reflects a $3.37 million noncash gain from revaluing warrant liabilities, compared with a $17.69 million noncash warrant loss in Q1 2017. The year-over-year net-loss comparison therefore does not represent a comparable change in operating performance.
- Rexahn recorded approximately $369,000 of other income after terminating its RX-0201 agreement with Next BT. The agreement termination eliminated a deferred liability; in return, Next BT is entitled to specified royalties and licensing proceeds on RX-0201 in Asia, capped at $5 million in aggregate.
- RX-3117 and RX-5902 R&D spending increased to approximately $2.11 million and $0.91 million, respectively. RX-0201 spending was approximately $0.15 million.
Outlook, risks, and contingencies
Management said cash, cash equivalents, and marketable securities were expected to fund current activities for at least 12 months from issuance of the financial statements. The company nevertheless expects continued losses and says additional capital will be needed to continue development; financing may not be available on acceptable terms, and insufficient capital could require reduced R&D activity.
Management expected RX-3117 and RX-5902 expenses to decrease later in 2018 as manufacturing campaigns concluded, and RX-0201 expenses to decrease as the kidney cancer trial wound down. These are expectations, not assured outcomes. The company cited clinical and regulatory uncertainty, dependence on CROs and other third parties, manufacturing and funding needs, and intellectual-property and partnering risks. Estimated costs to complete vendor R&D service agreements were approximately $10.27 million; agreements may generally be terminated with notice. A $1 million KRICT milestone had not been triggered. The filing reported no material change to previously disclosed risk factors and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review subsequent cash use and financing activity against management’s stated 12-month liquidity outlook.
- Assess clinical-trial progress, enrollment, and results for RX-3117 and RX-5902, and the status of the RX-0201 wind-down.
- Consider the potential dilution and valuation effects of 7,099,609 outstanding warrants and other outstanding equity awards; warrant fair value is a Level 3 estimate sensitive to assumptions.
- Verify the terms and potential payment obligations arising from the Next BT arrangement and the estimated vendor commitments.